美国食品药品监督管理局批准摘要:卡匹色替联合氟维司群用于激素受体阳性、人表皮生长因子受体2阴性且伴PIK3CA/AKT1/PTEN变异的局部晚期或转移性乳腺癌
美国食品药品监督管理局基于CAPItello-291随机双盲多中心试验批准卡匹色替联合氟维司群用于激素受体阳性、HER2阴性、伴PIK3CA/AKT1/PTEN变异且接受过至少一种内分泌治疗的局部晚期或转移性乳腺癌成人患者。该试验纳入708例患者,其中289例存在PIK3CA/AKT1/PTEN变异,总体人群无进展生存期风险比0.6(95%CI 0.51-0.71),生物标志物阳性人群风险比0.5(95%CI 0.37-0.68)。
要点
- 卡匹色替联合氟维司群获批用于伴PIK3CA/AKT1/PTEN变异的HR阳性/HER2阴性晚期或转移性乳腺癌。
- CAPItello-291总体人群PFS风险比0.6(95%CI 0.51-0.71),生物标志物阳性人群风险比0.5(95%CI 0.37-0.68)。
- 卡匹色替组≥3级毒性更多,关键关注包括高血糖、皮肤毒性和腹泻。
核心结论
- 卡匹色替联合氟维司群获批用于肿瘤携带PIK3CA/AKT1/PTEN变异的患者,该亚组基于PFS统计学显著且有临床意义的改善及可接受的安全性特征,获益-风险评估为有利。
- 生物标志物阴性人群的获益-风险评估为不利。
研究设计与样本
- 批准基于CAPItello-291随机、双盲、多中心试验,纳入708例激素受体阳性、HER2阴性晚期或转移性乳腺癌患者,其中289例存在PIK3CA/AKT1/PTEN肿瘤变异。
- 患者按1:1随机接受卡匹色替400 mg每日两次、每周用药4天联合氟维司群,或安慰剂联合氟维司群;随机分层因素包括肝转移、既往CDK4/6抑制剂治疗和地理区域。
主要发现
- 总体人群显示统计学显著的无进展生存期获益,风险比0.6(95%CI 0.51-0.71);该结果由289例生物标志物阳性患者驱动,风险比0.5(95%CI 0.37-0.68)。
- 在313例(44%)生物标志物阴性患者中,研究者评估的无进展生存期探索性分析显示获益不确定,风险比0.78(95%CI 0.60-1.01)。
- 卡匹色替组≥3级毒性更多;关键关注包括高血糖(全部级别18%,≥3级2.8%)、皮肤毒性(全部级别58%,≥3级17%)和腹泻(全部级别72%,≥3级9%)。
关键数值与推荐
- 美国食品药品监督管理局批准卡匹色替联合氟维司群用于成人激素受体阳性、HER2阴性、局部晚期或转移性乳腺癌患者,要求既往接受过至少一种内分泌治疗,且肿瘤经美国食品药品监督管理局批准的检测检出≥1种PIK3CA/AKT1/PTEN变异。
- 卡匹色替给药方案为400 mg每日两次、每周用药4天,联合氟维司群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The US Food and Drug Administration (FDA) approved capivasertib in combination with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, or metastatic breast cancer (MBC) who have received at least one previous endocrine therapy and whose tumors harbor one or more phosphatidylinositol 3-kinase (PIK3CA)/AKT Serine/Threonine Kinase 1 (AKT1)/phosphatase and tensin homolog (PTEN) alterations, as detected by an FDA-approved test. PATIENTS AND METHODS: Approval was based on CAPItello-291, a randomized, double-blind, multicenter trial of 708 patients with hormone receptor-positive, HER2-negative advanced or MBC, including 289 patients with PIK3CA/AKT1/PTEN tumor alterations. Patients were randomly assigned 1:1 to receive capivasertib 400 mg twice daily for 4 days per week with fulvestrant versus placebo with fulvestrant. Random assignment was stratified by presence of liver metastases, previous treatment with CDK4/6i, cyclin-dependent kinase four and six (CDK4/6) inhibitors, and geographical region. RESULTS: A statistically significant progression-free survival (PFS) benefit was demonstrated in the overall population (hazard ratio [HR], 0.6 [95% CI, 0.51 to 0.71]); this result was driven by 289 patients in the biomarker-positive population (HR, 0.5 [95% CI, 0.37 to 0.68]). An exploratory analysis of investigator-assessed PFS in the 313 (44%) patients in the biomarker-negative population showed uncertain benefit (HR, 0.78 [95% CI, 0.60 to 1.01]). With capivasertib, more patients had Grade ≥3 toxicities. Key concerns included hyperglycemia (18% all-grade, 2.8% Grade ≥3), cutaneous toxicity (58% all-grade, 17% Grade ≥3), and diarrhea (72% all-grade, 9% Grade ≥3). CONCLUSION: Capivasertib with fulvestrant was approved for patients whose tumors harbored PIK3CA/AKT1/PTEN alterations. Benefit-risk assessment in this subgroup was favorable based on a statistically significant and clinically meaningful improvement in PFS in the context of an acceptable safety profile including no evidence of a potential detriment in overall survival. By contrast, the benefit-risk was unfavorable in the biomarker-negative population.
引用
- Dilawari A, Buturla J, Osgood C, et al. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations. J Clin Oncol. 2024. PMID: 39159418. doi:10.1200/JCO.24.00427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。